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Abstract
Introduction The aim of this study was to describe the
epidemiology and management of acute lung injury (ALI) and the
acute respiratory distress syndrome (ARDS) in Ireland.
Methods As part of a 10-week prospective national audit of
patient demographics and organ failure incidence in intensive
care in Ireland, all patients with ALI/ARDS in 14 participating
centres were prospectively identified using American European
Consensus Conference definitions.
Results There were 1,029 admissions during the study period;
of these, 728 patients were invasively ventilated. A total of 196
(19%) patients had ALI/ARDS, and 141 of these (72%) had
ALI/ARDS on admission and a further 55 (28%) developed ALI/
ARDS after admission. For the patients with ALI/ARDS, the
mean (± standard deviation) age was 58 ± 17 years and 62%
were male. The most common predisposing risk factors were
pneumonia (50%) and nonpulmonary sepsis (26%). Mean (±
standard deviation) tidal volume/kg was 7.0 ± 1.7 ml/kg. Median
(interquartile range) duration of ventilation was 6.8 (2.0 to 12.8)
days. Median (interquartile range) length of stay in the intensive
care unit was 10.0 (5.0 to 18.5) days. The overall intensive care
unit mortality for ALI/ARDS was 32.3%. Lower baseline arterial
oxygen tension/fraction of inspired oxygen ratio and higher
Sequential Organ Failure Assessment scores were associated
with increased mortality. Although not significant, patients
receiving treatment with a statin during admission had a 73%
lower odds of death (odds ratio 0.27, 95% confidence interval
0.06 to 1.21; P = 0.09).
Conclusion The incidence of ALI/ARDS is high and is
associated with significant mortality. Protective lung ventilation
is used commonly throughout participating centres. With low
tidal volume ventilation, the degree of hypoxaemia is associated
with outcome. These data will inform future multicentre clinical
trials in ALI/ARDS in Ireland.
Introduction
Acute lung injury (ALI) and the acute respiratory distress syn-
drome (ARDS) occur in response to a variety of insults and are
characterized by the development of noncardiogenic pulmo-
nary oedema, impaired gas exchange and need for mechanical
ventilation. ALI/ARDS is a major cause of acute respiratory fail-
ure associated with significant morbidity and mortality. Deliv-
ery of critical care to patients with ALI/ARDS accounts for a
significant proportion of intensive care unit (ICU) capacity. The
mean cost per ICU bed-day is n2,000 [1] and demand for ICU
beds exceeds supply.
Many pharmacological treatments for lung injury have been
evaluated, but none have clearly decreased mortality [2]. There
is therefore an urgent need to develop novel treatment strate-
gies for patients with ALI/ARDS. Notably, statins – a promising
potential new therapeutic option – modulate mechanisms that
are important in the development of lung injury [3]. Statins
attenuate lung injury in vivo in animal models, including
ischemia-reperfusion [4], peritonitis [5] and endotoxaemic
sepsis [6].
The Irish Critical Care Trials Group (ICCTG) was formed in
2006 with the aim of improving the capacity to conduct high
quality clinical research in the critically ill in Ireland. In order to
AECC = American European Consensus Conference; ALI = acute lung injury; ARDS = acute respiratory distress syndrome; CRSC = Clinical 
Research Support Centre; FiO2 = fraction of inspired oxygen; ICCTG = Irish Critical Care Trials Group; ICU = intensive care unit; PaO2 = arterial 
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inform hypotheses, feasibility and design of multicentre clinical
trials, there was a need to define first the epidemiology of the
potential study population. Accordingly, the ICCTG con-
ducted a prospective 10-week national audit of patient demo-
graphics and organ failure incidence in intensive care in
Ireland.
The purpose of this article is to report on the cohort of patients
within the study group with ALI/ARDS in the Irish adult ICU
population in order to determine the incidence, aetiologies and
mortality of ALI/ARDS; to establish factors associated with
outcome; to identify whether standardized care is being deliv-
ered across participating centres in a research network; and
to investigate whether treatment with statins is beneficial to
provide pilot data for subsequent clinical trials.
Materials and methods
A prospective 10-week national audit of patient demographics
and organ failure incidence in intensive care in Ireland was
conducted across the 14 general ICUs that form the ICCTG.
Local research ethics committee approval was required and
granted in nine centres. The need for informed patient consent
was waived by the local ethics committees in these centres.
Research ethics committee approval was not required at the
other centres (in which the project was categorized as audit)
because patient management was not altered, only routinely
collected data were used and the data were fully anonymized.
These centres include a combination of general units of vary-
ing size and tertiary referral ICUs, including three ICUs with
neurosurgical beds.
As part of this audit, all patients admitted to the ICU were
screened daily during their entire admission for the develop-
ment of ALI/ARDS. Patients were included in the study if they
fulfilled the American European Consensus Conference
(AECC) criteria [7] for ALI/ARDS (acute onset of bilateral infil-
trates on chest radiograph; arterial oxygen tension [PaO2]/
fraction of inspired oxygen [FiO2] ratio <40 kPa for ALI and
<27 kPa for ARDS; and absence of cardiac failure or left atrial
hypertension [assessed clinically, echocardiographically, or
with invasive monitoring]) and required invasive ventilation.
Patients were defined as having ALI/ARDS on admission if cri-
teria were fulfilled within 48 hours of admission. If criteria were
fulfilled after 48 hours, then patients were categorized as
developing ALI/ARDS after admission.
Standard demographic data including individual organ and
total Sequential Organ Failure Assessment (SOFA) score [8]
were collected daily each morning between 08:00 and 10:00
hours on all patients until ICU discharge. When a patient was
identified as having ALI/ARDS, additional data including aeti-
ology of ALI/ARDS, ventilator settings and respiratory varia-
bles (including tidal volume [Vt] normalized to actual body
weight [Vt/kg]), and therapy (including whether the patients
received a statin) were recorded. The PaO2/FiO2 ratio at diag-
nosis and ventilator settings and respiratory variables (includ-
ing Vt/kg and plateau pressure) as well as SOFA score were
recorded on the day of diagnosis and then daily each morning
between 08:00 and 10:00. Duration of mechanical ventilation
and survival status at ICU discharge were recorded.
A form summarizing all ICU admissions and discharges during
the previous 24 hours was submitted daily. The total number
of ICU admissions determined from the daily report was used
to confirm that all patients were included. In addition, this
served as a control function to ensure that the participating
centres remained active and screened patients throughout the
study period. The principal ICU investigator at each centre
was responsible for data validation before submission to the
coordinating Clinical Research Support Centre (CRSC). Tele-
phone and e-mail assistance from the CRSC was available.
The data were entered onto a database at the CRSC and then
reviewed for inconsistencies and data entry errors.
Statistical analysis
Proportions were used as descriptive statistics for categorical
variables, mean ± standard deviation for normally distributed
continuous variables, and median (interquartile range) was for
non-normally distributed continuous variables. Pearson's χ2
test was used to compare categorical variables. To analyze
ICU mortality, a backward stepwise logistic regression model
was employed to choose from among variables that were
associated with mortality and felt to be clinically important.
Consequently, age, sex, aetiology, SOFA score, PaO2/FiO2
ratio, plateau pressure, Vt/kg, arterial carbon dioxide tension
and use of statins were included. P < 0.05 was considered
statistically significant. All analyses were performed using
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Data were collected on 1,029 admissions during the study
period between 7 August and 20 October 2006; of these
patients, 728 were mechanically ventilated. A total of 196
(19%) patients had ALI/ARDS, of whom 141 (72%) had ALI/
ARDS on admission and a further 55 (28%) patients devel-
oped ALI/ARDS after admission. Patient demographics are
summarized in Table 1.
The overall rate of ICU mortality from ALI/ARDS was 32.3%.
There was no significant difference in mortality if ALI/ARDS
was present on admission or if it developed after admission
(32.8 versus 30.9%, respectively). Patients with ALI had a sig-
nificantly lower mortality compared with patients with ARDS
(21.0 versus 37.8%, respectively; P = 0.02).
Of the patients with ALI/ARDS, a greater proportion were in
the older age groups (Figure 1a). However, this merely
reflected the age demographics of ICU admissions, because
the age-specific incidence was similar in each age groupAvailable online http://ccforum.com/content/12/1/R30
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(Figure 1b). There was no significant difference in mortality
according to age (Figure 1a).
The most common risk factor for ALI/ARDS was pneumonia
followed by nonpulmonary sepsis. There was no significant dif-
ference in mortality according to risk factor (Figure 2).
On the day of diagnosis of ALI/ARDS, patients received
mechanical ventilation with a mean Vt of 7.0 ± 1.7 ml/kg actual
body weight (corresponding to approximately 8.4 ± 2.0 ml/kg
predicted body weight). Fourteen per cent were ventilated
using a Vt of 5 ml/kg or less (approximately 6 ml/kg predicted
body weight), with only 5% ventilated using a Vt above 10 ml/
kg (approximately 12 ml/kg predicted body weight; Figure 3a).
Although mortality increased with increasing Vt, this was not
significant (Figure 3b). There was no significant variation
between participating centres in Vt/kg (data not shown). Mean
positive end-expiratory pressure (PEEP) was 7.7 ± 2.8
cmH2O.
As the PaO2/FiO2 ratio on the day of diagnosis of ALI/ARDS
increased, mortality decreased (P  = 0.009; Figure 4). ICU
mortality was 48.9% for those with a PaO2/FiO2 ratio under 15
and 20% in those with a PaO2/FiO2 ratio above 30. There was
no significant correlation between Vt/kg and PaO2/FiO2 ratio.
Mortality was significantly increased in the patients with the
highest SOFA score on the day of diagnosis of ALI/ARDS (P
= 0.001; Figure 5). Only 12% of patients had a plateau pres-
sure above 30 cmH2O. Plateau pressure was not associated
with mortality. There was no significant correlation between Vt/
kg and plateau pressure. Arterial carbon dioxide tension was
not associated with mortality.
Data on statin use during admission was available for 188
patients. Mortality in the 24 patients who received statins dur-
ing their ICU stay was reduced compared with mortality in the
patients who did not, although this difference was not statsti-
cally significant (20.8% versus 33.5%; P = 0.2; Figure 6). The
demographics and reason for admission of the patients who
received statins are shown in Tables 2 and 3, respectively. The
Table 1
Demographic details in patients with ALI/ARDS
Parameter Value
Age (years; mean ± SD) 58 ± 17
Male (n [%]) 120 (62)
SOFA score on day ALI/ARDS diagnosed (mean ± SD) 8.8 ± 4.1
PaO2/FiO2 ratio (mean ± SD) 22.7 ± 9.1
Plateau pressure (cmH2O; mean ± SD) 21.5 ± 6.8
pH (mean ± SD) 7.34 ± 0.15
PCO2 (kPa; mean ± SD) 5.8 ± 1.6
PEEP (cmH2O; mean ± SD) 7.7 ± 2.8
Duration of ventilation (days; median [IQR]) 6.0 (2.0 to 12.8)
ICU length of stay (days; median [IQR]) 10.0 (5.0 to 18.5)
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; FiO2, fraction of inspired oxygen; ICU, intensive care unit; IQR, interquartile 
range; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; PEEP, positive end-expiratory pressure; SD, standard deviation; 
SOFA, Sequential Organ Failure Assessment.
Figure 1
Patients with ALI/ARDS stratified by age and relative to all admissions Patients with ALI/ARDS stratified by age and relative to all admissions. 
(a) Proportion of patients with acute lung injury (ALI)/acute respiratory 
distress syndrome (ARDS) in each age group and (b) proportion of 
patients with ALI/ARDS relative to all admissions in each age group.Critical Care    Vol 12 No 1    McAuley and 
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patients who received statins were older but there was no
other significant difference between patients who received
statins and those who did not.
Table 4 shows the variables that were independently associ-
ated with mortality in the multiple logistic regression model.
Only PaO2/FiO2 ratio and organ dysfunction, as measured
using SOFA score, were associated with mortality. Although
not significant, patients receiving statins had a 73% lower
odds of death (odds ratio 0.27, 95% confidence interval 0.06
to 1.21; P = 0.09).
Discussion
In this multicentre survey, we found that ALI/ARDS occurred
in approximately 19% of all ICU admissions. Although the inci-
dence is high, it is in keeping with recent well designed epide-
miological studies that have estimated the incidence of ALI/
ARDS to be 15% to 26% in patients mechanically ventilated
for more than 24 hours [9,10]. Because mechanical ventilation
was included in our definition of ALI/ARDS, which is not a
requirement in the AECC criteria, it is likely that this is a con-
servative estimate of the incidence of ALI/ARDS.
The crude ICU mortality for ALI/ARDS was lower compared
with recent European findings, which estimate the mortality of
ARDS at 49% to 53% [9,11]. The mortality rate in this study
is in keeping with mortality reported in ARDSnet studies that
have utilized protective lung ventilation [12-14]. The lower
mortality in this study may reflect the use of a lower Vt strategy.
The mean Vt in this study was 7.0 ml/kg (approximately 8.4 ml/
kg predicted body weight), as compared with a mean Vt in the
European ALIVE study of 8.3 ml/kg (approximately 10.0 ml/kg
predicted body weight) [9] and 9.2 ml/kg (approximately 11.0
ml/kg predicted body weight) in a Scottish study [11]. These
data suggest advances in the ventilatory management of ALI/
ARDS have translated into practice, which is contrast to evi-
dence that many centres still do not apply protective lung ven-
tilation strategies [15,16].
Consistent with previous studies, organ dysfunction predicts
mortality in ALI/ARDS [9,17,18]. We found the PaO2/FiO2
ratio at diagnosis of ALI/ARDS to be associated with mortality.
This is contrary to most [19-21] but not all [9] previous reports
in ALI/ARDS. The reports demonstrating no association with
PaO2/FiO2 ratio are older and predate the era of protective
lung ventilation. With low Vt ventilation the aim of mechanical
ventilation is limitation of ventilator-associated lung injury
rather than correction of hypoxaemia. As a result, oxygenation
Figure 2
Clinical risk factors for ALI/ARDS and associated risk for mortality Clinical risk factors for ALI/ARDS and associated risk for mortality. ALI, 
acute lung injury; ARDS, acute respiratory distress syndrome.
Figure 3
Mean tidal volume Mean tidal volume. Mean tidal volume (normalized to actual body 
weight) recorded on the day of diagnosis of acute lung injury/acute res-
piratory distress syndrome: (a) frequency distribution and (b) associ-
ated mortality.
Figure 4
Mortality associated with PaO2/FiO2 ratio quartiles on the day of diag- nosis of ALI/ARDS Mortality associated with PaO2/FiO2 ratio quartiles on the day of diag-
nosis of ALI/ARDS. ALI, acute lung injury; ARDS, acute respiratory dis-
tress syndrome; FiO2, fraction of inspired oxygen; PaO2, arterial oxygen 
tension.Available online http://ccforum.com/content/12/1/R30
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may be more likely to reflect severity of pulmonary dysfunction
and outcome. This is supported by the finding there is no cor-
relation between Vt/kg and PaO2/FiO2 ratio at diagnosis of
ALI/ARDS, which suggests that clinicians do not react to
worse oxygenation by using higher Vts. It is also important to
consider that the PaO2/FiO2 ratio is highly variable, depending
on the ventilatory strategy employed as well as the distribution
of ventilation-perfusion, which is influenced by the pattern of
mechanical ventilation (including PEEP and I:E ratio) [22]. It is
relevant that the initial PaO2/FiO2  ratio was predictive of
outcome in several large clinical trials that implemented a
protocolized ventilatory strategy [12,23]. In the present study,
although ventilatory strategy was not protocolized, and in par-
ticular PEEP/FiO2  combinations were not mandated, one
possible explanation for the finding that the initial PaO2/FiO2
ratio was associated with mortality is that ventilatory strategy
was sufficiently standardized, which is supported by the close
adherence to protective lung ventilation strategy. However, it
should also be recognized that physiological indices such as
cardiac output may also affect the PaO2/FiO2 ratio and may
have influenced the relationship between PaO2/FiO2 ratio and
mortality. Finally, it is acknowledged that these data relate to
PaO2/FiO2 ratio and Vt on the day of diagnosis of ALI/ARDS,
and the influence of any subsequent alteration in Vt on the rela-
tionship between P/F ratio and mortality is unknown.
Vt was not associated with mortality in this study, which is not
surprising given the relatively good adherence to lung protec-
tive ventilation, with only 5% of patients of patients receiving a
tidal volume above 10 ml/kg. This is in accordance with previ-
ous trials of protective lung ventilation, in which benefit was
only seen where there was the largest difference between the
lower and higher Vt strategies [12,24].
Plateau pressure was not related to mortality in this study, in
contrast to data describing a direct relationship between pla-
teau pressure and mortality [25,26]. Similarly to the contention
that there is no relationship with Vt, this may reflect adherence
to lung protective ventilation, with only 12% of patients having
a plateau pressure above 30 cmH2O. Furthermore, because
plateau pressure is determined by multiple factors, including Vt
(with possible harmful effects as Vt increases) and PEEP (with
possible beneficial effects as PEEP increases [26]), it is pos-
sible that this finding reflects opposing influences of Vt and
PEEP in lung injury. We did not define how plateau pressure
was to be measured. In addition, 75% of patients received
pressure-controlled ventilation, in which inspiratory pressures
may overestimate plateau pressure. It is possible that these
factors influenced the relationship between plateau pressure
and mortality.
Contrary to our findings, age [9,11,17] and duration of ventila-
tion pre-ALI/ARDS [17] have been associated with increased
mortality in ALI/ARDS. It is possible that as a result of selection
bias elderly patients who were admitted to ICU were less
severely ill and had less co-morbidity, which confounded the
correlation of age with mortality in our study. Although in some
studies risk factors for ALI were found to be associated with
mortality [19,27], this has not been a universal finding [9,28],
Figure 5
Mortality associated with organ dysfunction on day of diagnosis of ALI/ ARDS Mortality associated with organ dysfunction on day of diagnosis of ALI/
ARDS. Organ dysfunction was assessed based on Sequential Organ 
Failure Assessment score quartiles. ALI, acute lung injury; ARDS, acute 
respiratory distress syndrome.
Table 2
Demographic details of patients who received a statin
Parameter Received a statin Did not receive a statin P
Age (years; mean ± SD) 67.8 (12.4) 56.7 (17.5) 0.01
Male (n [%]) 13 (56.5) 106 (62.0) 0.61
SOFA score on day ALI/ARDS diagnosed (mean ± SD) 8.1 (3.9) 8.9 (4.1) 0.39
PaO2/FiO2 ratio (mean ± SD) 20.7 (8.9) 23.0 (9.1) 0.24
Plateau pressure (cmH2O; mean ± SD) 23.6 (5.8) 21.2 (6.9) 0.13
pH (mean ± SD) 7.37 (0.10) 7.33 (0.16) 0.24
PCO2 (kPa; mean ± SD) 6.0 (1.5) 5.8 (1.6) 0.59
PEEP (cmH2O; mean ± SD) 8.3 (3.2) 7.6 (2.7) 0.29
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; FiO2, fraction of inspired oxygen; PaO2, arterial oxygen tension; PaCO2, arterial 
carbon dioxide tension; PEEP, positive end-expiratory pressure; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.Critical Care    Vol 12 No 1    McAuley and 
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and no such relationship existed in our study. It is more likely
that the severity of physiological derangement and organ
dysfunction, as in our findings, are more important determi-
nants of outcome.
Accurate epidemiological data are essential to provide pilot
data as well as to inform the design and feasibility assessment
of clinical trials. These prospective data from an unselected
cohort of critically ill patients with ALI/ARDS provide important
information to inform phase III clinical trials.
In a study in which mortality is the primary outcome, overesti-
mating the mortality rate in the power calculation will result in
the study being under-powered. If the mortality rate of 49%
from European epidemiological data [9] were used to deter-
mine the required sample size for an ALI/ARDS study in Ire-
land, where the mortality is lower, this would result in a large
and expensive phase III study being significantly under-pow-
ered. Another important consideration that may result in over-
estimation of the current mortality rate for ALI/ARDS is that the
European ALIVE study [9] was undertaken in 1999, before the
publication of definitive evidence regarding the role of low Vt
ventilation, and subsequent studies showing low adherence to
protective lung ventilation [11,15,16] were undertaken rela-
tively soon after publication of the ARDSnet study findings that
confirmed benefit. With more widespread adherence to pro-
tective lung ventilation, as suggested in this current study, it
might be expected that mortality is lower. This has important
implications for multicentre studies being performed across
Europe.
Furthermore, if the expected mortality benefit from pilot data is
small, then powering a study with mortality as the primary out-
come may not be possible, because the sample size would be
too large to allow recruitment within an acceptable time
period. On the basis of such factors, it may be necessary to
consider other important clinical end-points such as ventilator-
free days in order to design an feasible trial. In addition, these
data will inform the decision regarding whether a clinical study
could successfully be undertaken nationally or would require
multinational trial group co-operation in order to recruit the
numbers required.
In undertaking multicentre trials it is essential to demonstrate
standardized care between centres. It is reassuring that in this
unselected population the standardization of ventilatory strat-
egy was already apparent, with use of lower Vts, and that out-
comes are in keeping with international standards [13,14].
Table 3
Reason for admission in patients who received a statin
Diagnosis Number of patients
Pneumonia 7
Nonpulmonary sepsis 4
Respiratory failure 5
Postoperative (AAA repair) 3
ARDS – no aetiology specified 1
Post cardiac arrest 1
Haemorrhagic shock post-IVC filter insertion 1
Neutropenic sepsis, pneumonia, Churg-Strauss syndrome 1
Sarcoidosis 1
In all, 24 patients received statin treatment. AAA, abdominal aortic aneurysm; ARDS, acute respiratory distress syndrome; IVC, inferior vena cava.
Figure 6
Mortality in patients with ALI/ARDS receiving treatment with a statin  during admission Mortality in patients with ALI/ARDS receiving treatment with a statin 
during admission. ALI, acute lung injury; ARDS, acute respiratory dis-
tress syndrome.
Table 4
Multiple regression model on intensive care unit mortality
Variable OR (95% CI) p value
PFratio (per 1 unit) 0.91 (0.86–0.97) 0.004
SOFA Score (per point) 1.26 (1.09–1.45) 0.001
Treatment with statins:
No Reference
Yes 0.27 (0.06–1.21) 0.09
CI, confidence interval; OR, odds ratio; SOFA, Sequential Organ 
Failure Assessment.Available online http://ccforum.com/content/12/1/R30
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There is experimental and preclinical evidence that statins [3]
may be beneficial in ALI/ARDS. The present study supports an
association with improved outcome in patients who received
statin therapy. The patients who received statins reflected the
general population included in this study. These data are inter-
esting and valuable in terms of generating hypotheses. How-
ever, it must be emphasized that the numbers of patients
receiving statins were small and that subsequent randomised
clinical trials examining statins in ALI/ARDS will be required. A
major limitation is that no information was collected on the
specific statin or dose administered, which may be important
in determining possible benefit. In addition, no information is
available on how many patients not receiving statins during
their ICU admission had received statins before admission. A
further confounding issue is that sicker patients would per-
haps be less likely to receive their statin because of potential
concerns about increased toxicity or failure of the enteral route
in this group.
There are a number of limitations to our study. With the diag-
nosis of ALI/ARDS based on AECC criteria, it is recognized
that misclassification may occur because of misinterpretation
of chest radiographs and exclusion of left atrial hypertension
on clinical assessment only. However, misclassification is no
more likely in this study than in similar epidemiological studies
using these current definitions. Data on co-morbidities were
not collected. The influence of co-morbidities on overall
mortality as well as the potential effect of statins may be impor-
tant, but this cannot be quantified from the data presented
here. Additionally, height was not recorded, and therefore it is
not possible to calculate predicted body weight accurately to
adjust Vt. For comparison with the ARDSnet protective lung
ventilation study actual body weight has been estimated at
20% greater than predicted body weight, and approximate val-
ues for Vt/predicted body weight have been presented [12].
Data were collected over a 10-week period and seasonal
variation in the incidence of ALI/ARDS, although unlikely, can-
not be excluded.
Conclusion
The incidence of ALI/ARDS is high and is associated with sig-
nificant mortality. Protective lung ventilation, which is known to
be associated with lower mortality, is used commonly. There is
standardized care throughout participating centres. The high
mortality associated with the condition emphasizes the need
for clinical trials in ALI/ARDS. These data will help to inform
the design of subsequent multicentre clinical trials in ALI/
ARDS.
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